The Chemours Company (CC) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
5 Nov, 2026Executive summary
Q3 net sales rose 3% YoY to $1.54B; Adjusted EBITDA increased 6% to $200M, led by TT pricing and APM growth, partly offset by TSS weakness and higher costs.
GAAP net income was $196M, or $1.29/share, including $150M of PFAS insurance proceeds; Adjusted Net Income was $31M.
Execution included debt reduction, cost and operating initiatives, environmental settlements, and completion of the Kuan Yin land sale.
Financial highlights
Net sales were $1.54B, up $45M YoY and down $51M QoQ; pricing rose 5%, volumes fell 2%, and currency was a slight headwind.
Adjusted EBITDA was $200M, up $11M YoY and down $47M QoQ; adjusted net income was $31M and adjusted diluted EPS was $0.21.
Operating cash flow was $149M, capex $51M, and free cash flow $98M; Q3 free-cash-flow conversion was 49% versus 56% a year earlier.
GAAP net income of $196M included $150M of PFAS insurance proceeds and Kuan Yin land-sale gains; Q3 COGS rose 4% amid higher unit costs and lower production rates.
Nine-month net sales were $4.51B; net loss was $107M, including a $307M tax provision and substantial environmental and litigation charges.
Outlook and guidance
FY2026 net sales are expected to grow ~2%; Adjusted EBITDA guidance is $775M–$800M, capex $220M–$230M, free-cash-flow conversion 15%–20%, and net leverage below 4.2x.
Q4 net sales are expected to decline 5%–10% sequentially; Adjusted EBITDA is forecast at $160M–$185M, with positive free cash flow.
Q4 TSS sales are expected to decline high-teens to low-twenties sequentially, with Adjusted EBITDA of $105M–$115M; TT sales are expected down high-single digits to low-teens, with EBITDA of $60M–$65M.
Q4 APM sales are expected to rise low- to mid-teens sequentially, with Adjusted EBITDA of $40M–$45M, supported by Performance Solutions orders.
Earnings growth is expected in 2027 despite macro uncertainty; expected environmental remediation spending over three years is $227M at five significant sites and $63M at other sites.
Latest events from The Chemours Company
- Q2 2026 delivered strong cash flow, margin expansion, and strategic progress in high-growth markets.CC
Investor presentation - Adjusted EBITDA was $247M on flat sales, with improved cash flow and lower net loss year-over-year.CC
Q2 2026 - Virtual annual meeting set for April 2026 with key votes on directors, pay, and auditor.CC
Proxy filing - TSS strength drove $1.4B sales and $169M EBITDA, despite wider net loss and TT/APM declines.CC
Q1 2026 - 2025 net sales reached $5.8B, driven by Opteon growth, cost savings, and asset optimization.CC
Investor presentation - Board refreshment, strategic execution, and ESG progress headline this year's proxy.CC
Proxy Filing - TSS Opteon™ growth and strong cash flow drive 2026 outlook amid TT/APM headwinds.CC
Q4 2025 - Q3 2024 featured strong Opteon™ growth, TT margin gains, and ongoing cost reduction initiatives.CC
Investor presentation - Chemours targets growth in refrigerants and data center cooling while managing PFAS liabilities.CC
Gabelli Funds' 16th Annual Specialty Chemicals Symposium